Positive Press Coverage Very Likely to Impact Epizyme (EPZM) Stock Price
Media stories about Epizyme (NASDAQ:EPZM) have trended positive recently, according to AlphaOne. The research group, a subsidiary of Accern, identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Epizyme earned a media sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also assigned news headlines about the biopharmaceutical company an impact score of 81 out of 100, meaning that recent press coverage is very likely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted AlphaOne Sentiment Analysis’s scoring:
- Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO (finance.yahoo.com)
- Epizyme Inc (EPZM) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Epizyme (EPZM) Earning Positive Press Coverage, Report Finds (americanbankingnews.com)
- Somewhat Positive Media Coverage Extremely Likely to Effect Epizyme (EPZM) Share Price (americanbankingnews.com)
Epizyme (NASDAQ:EPZM) traded down 2.68% during trading on Friday, hitting $14.55. 177,054 shares of the company were exchanged. The company’s market capitalization is $847.51 million. The company has a 50-day moving average of $15.91 and a 200-day moving average of $12.17. Epizyme has a 12 month low of $7.02 and a 12 month high of $17.80.
Epizyme (NASDAQ:EPZM) last announced its earnings results on Thursday, March 9th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.05. The business earned $0.48 million during the quarter, compared to the consensus estimate of $0.61 million. Epizyme had a negative net margin of 1,205.01% and a negative return on equity of 41.56%. Analysts forecast that Epizyme will post ($2.55) EPS for the current year.
EPZM has been the subject of a number of research analyst reports. Cann reaffirmed an “outperform” rating and set a $26.00 price objective on shares of Epizyme in a research report on Wednesday, April 12th. Oppenheimer Holdings Inc. initiated coverage on shares of Epizyme in a research report on Thursday, April 13th. They set an “outperform” rating and a $26.00 price objective for the company. CIBC reaffirmed an “outperform” rating on shares of Epizyme in a research report on Thursday, April 13th. Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Wednesday, December 28th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $19.00 price objective (down previously from $26.00) on shares of Epizyme in a research report on Saturday, March 11th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $23.88.
COPYRIGHT VIOLATION NOTICE: “Positive Press Coverage Very Likely to Impact Epizyme (EPZM) Stock Price” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/04/21/positive-press-coverage-very-likely-to-impact-epizyme-epzm-stock-price.html.
In other news, CFO Andrew E. Singer sold 2,013 shares of the company’s stock in a transaction on Friday, March 31st. The shares were sold at an average price of $17.09, for a total value of $34,402.17. Following the completion of the transaction, the chief financial officer now directly owns 36,175 shares in the company, valued at $618,230.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Robert A. Copeland sold 5,000 shares of the company’s stock in a transaction on Tuesday, April 4th. The shares were sold at an average price of $16.36, for a total transaction of $81,800.00. Following the completion of the transaction, the insider now owns 33,538 shares of the company’s stock, valued at $548,681.68. The disclosure for this sale can be found here. 25.40% of the stock is currently owned by corporate insiders.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Stock Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related stocks with our FREE daily email newsletter.